Drug intelligence / Profile preview

Coricidin

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Coricidin is a brand of over-the-counter combination medications used to treat symptoms associated with the common cold, influenza, and allergies. Originally introduced by Schering-Plough in 1949 and currently owned by Bayer, the product line is most distinguished by its "HBP" (High Blood Pressure) formulations. These versions are specifically designed for patients with hypertension as they omit decongestants like pseudoephedrine or phenylephrine, which are known to increase blood pressure. The typical active ingredients include chlorpheniramine maleate (a first-generation antihistamine), dextromethorphan hydrobromide (a cough suppressant), and acetaminophen (an analgesic and antipyretic). Together, these components provide relief from sneezing, runny nose, cough, minor aches, and fever through H1 receptor antagonism, sigma-1 receptor agonism, NMDA receptor inhibition, and cyclooxygenase inhibition.

Brand names
CoricidinCoricidin HBP
Other names
chlorpheniramine maleate + dextromethorphan hydrobromide
02

Targets

NET (Norepinephrine Transporter)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DAT (Dopamine plasma membrane transport protein)PGHS-1 (Prostaglandin G/H Synthase 1)SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Coricidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coricidin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call